BioCorRx stock analysis
Want to see BICX full AI Analyst Report?
BioCorRx (BICX) Stock Price & Analysis
BICX Stock Chart & Stats
- Day’s Range
- $0.21 - $0.21
- 52-Week Range
- $0.15 - $1.28
- Previous Close
- $0.21
- Volume
- N/A
- Average Volume (3M)
- 662
- Market Cap
- $6.28M
- Enterprise Value
- $17.35M
- Total Cash (Recent Filing)
- $18.23K
- Total Debt (Recent Filing)
- $2.30M
- Price to Earnings (P/E)
- ―
- Beta
- -0.03
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Gross Profit Margin
TTM gross margin of about 61% indicates the reported offerings retain meaningful gross profit despite the revenue contraction. If revenue stabilizes, this unit-level economics could support operating leverage, although current losses show that gross profit is not yet sufficient to fund the business.
Reduced Losses Versus 2024
Narrower losses than in 2024 provide evidence of some improvement in operating performance from an extremely weak base. This could become meaningful if sustained, but the current scale of losses means the improvement has not yet established a self-funding or consistently profitable business model.
Improved Operating Cash Flow
The reduction in operating cash burn versus 2025 is a constructive direction in cash management. Sustaining further improvement would extend financial runway and reduce funding pressure, although cash generation remains materially negative and the company still depends on external capital to operate.
Bears Say
Severe Revenue Contraction
An approximately 86% TTM revenue decline signals substantial deterioration in demand, commercialization, or business activity. Such a sharp contraction reduces operating scale, makes fixed costs harder to absorb, and undermines confidence that the company can rebuild a durable revenue base over the next several quarters.
Negative Equity And Thin Asset Base
Persistent negative equity and debt exceeding total assets materially weaken financial flexibility and increase solvency and dilution risk. The thin asset base provides limited balance-sheet support for obligations, leaving fewer options to fund operations, absorb setbacks, or invest without external financing.
Persistent Cash Burn And Unprofitability
Negative operating and free cash flow across every reported period, combined with a roughly -402% TTM net margin, shows that the business is not currently self-sustaining. Continued losses consume resources and make reliance on external funding a central constraint on future execution and growth.
BioCorRx News
BICX FAQ
What was BioCorRx’s price range in the past 12 months?
What is BioCorRx’s market cap?
When is BioCorRx’s upcoming earnings report date?
How were BioCorRx’s earnings last quarter?
Is BioCorRx overvalued?
Does BioCorRx pay dividends?
What is BioCorRx’s EPS estimate?
How many shares outstanding does BioCorRx have?
What happened to BioCorRx’s price movement after its last earnings report?
Which hedge fund is a major shareholder of BioCorRx?
What is the TipRanks Smart Score and how is it calculated?
Company Description
BioCorRx
BioCorRx Inc. (BICX), through its various operations, is dedicated to creating and delivering therapeutic solutions for individuals struggling with substance dependence and related health conditions across the United States. Among its core offerings is the BioCorRx recovery program, an innovative, non-addictive treatment model. This program uniquely combines proprietary naltrexone implants with extensive counseling services to support patient recovery. Additionally, the company provides the UnCraveRx weight management program, a medically supported initiative designed to curb food cravings. This program integrates pharmacological assistance with readily available virtual support focusing on lifestyle adjustments, fitness, and nutritional guidance. Looking to the future, BioCorRx is actively advancing its product pipeline. This includes BICX101, an injectable naltrexone product, and BICX104, an implantable naltrexone device, both currently under development for the specific treatment of opioid addiction and alcoholism. The company's programs are made available to patients through a network of healthcare providers, independent licensed clinics, and other qualified healthcare professionals. Originally established as Fresh Start Private Management, Inc., the organization officially rebranded as BioCorRx Inc. in January 2014. Its corporate headquarters are situated in Anaheim, California.
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- CEO
- Lourdes Felix
- Employees
- 3
- Website
- www.biocorrx.com
- Address
- 2390 East Orangewood Avenue, Anaheim, CA, 92806, US
BioCorRx (BICX) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 10 | 3 | 8 |
| Technical Analysis | 6 | 3 | 0 |
| Moving Averages | 4 | 0 | 8 |





